Modified immune cells for recent type 1 diabetes
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This study tests a new immune therapy using your own modified cells to try to stop type 1 diabetes from getting worse. It is for young adults who were recently diagnosed and still make some insulin.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 35 years old.
- You must have been diagnosed with type 1 diabetes within the past 1 to 2 years.
- You must test positive for at least one diabetes-related autoantibody (other than insulin antibodies).
- You must have some remaining insulin production, measured by a C-peptide test.
- You must be willing to wear a continuous glucose monitor and attend follow-up visits for up to 15 years.
- You must be willing to stop taking non-insulin diabetes pills for at least 30 days before starting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study follows children who are at genetic risk for type 1 diabetes or have early immune signs (autoantibodies) but do not yet need insulin. It provides extra checkups and information to catch the disease early and help families understand their child's risk.
This early-stage trial tests a new type of immune cell therapy (CAR-T cells) designed to stop the body's immune system from attacking insulin-producing cells in type 1 diabetes. The goal is to help preserve remaining pancreas function in people with early-stage disease.
This trial tests whether giving your own regulatory T cells (a type of immune cell) back to you can help slow or stop the immune attack on your pancreas in type 1 diabetes. It is for people aged 8 to 65 who still make some insulin.
This trial tests a new one-time treatment called CARC-101C for people recently diagnosed with type 1 diabetes. It aims to see if this treatment can help preserve the body's ability to make insulin and improve blood sugar control.
This trial tests a new combination treatment for children who have been diagnosed with stage 1 type 1 diabetes, meaning they have some markers but do not yet need insulin. The treatment uses special immune cells (Treg cells) and an antibody (anti-CD20) to try to preserve the body's ability to make insulin.
This trial tests a new cell injection (CNK-UT009) for adults with type 1 diabetes. The goal is to see if it can help manage blood sugar and reduce insulin needs.
Hear when a new Stage 3 Type 1 Diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.